Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-25-009099
Filing Date
2025-02-04
Accepted
2025-02-04 16:05:59
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm253006d3_defa14a.htm DEFA14A 11888
2 GRAPHIC tm253006d3_defa14aimg001.jpg GRAPHIC 179219
3 GRAPHIC tm253006d3_defa14aimg002.jpg GRAPHIC 95730
  Complete submission text file 0001104659-25-009099.txt   392238
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37939 | Film No.: 25588136
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)